Bayer Acquires Marketing Rights for Levitra | Business| Economy and finance news from a German perspective | DW | 10.01.2005
  1. Inhalt
  2. Navigation
  3. Weitere Inhalte
  4. Metanavigation
  5. Suche
  6. Choose from 30 Languages


Bayer Acquires Marketing Rights for Levitra

German chemicals and pharmaceuticals giant Bayer said Monday it had acquired the marketing rights for GlaxoSmithKline's erectile dysfunction treatment Levitra in a number of countries outside the US for €208 million (272 million dollars). Bayer said in a statement that it had signed an agreement with GlaxoSmithKline to buy the rights for Levitra in major markets in Europe, the Asia-Pacific region, Africa, Latin America and Canada. Previously, Bayer and GSK had shared the promotion of the drug in those regions. The German company said the deal would knock around €118 million off operating profit in the first quarter of 2005, but that the transaction would begin to have a positive effect on earnings from 2006. "The decision to buy back Levitra co-promotion rights is a logical step to enhance our pharmaceuticals business in Europe, Latin America and Asia," said Bayer Pharma chief Wolfgang Plischke.